Faheem Hasnain is the Chairman, President, and Chief Executive Officer of Gossamer Bio, Inc., a clinical-stage biopharmaceutical company dedicated to developing therapies in immunology, inflammation, and oncology. With over 25 years of experience in the life sciences industry, Hasnain has built a distinguished career leading innovative companies through critical stages of growth, from early-stage development to commercialization. His leadership expertise spans executive roles at multiple biotech firms, including serving as CEO of Aerpio Therapeutics, where he oversaw the advancement of novel therapeutics for metabolic and fibrotic diseases, and as President and COO of Akebia Therapeutics, guiding the company through its IPO and the development of its lead hypoxia-inducible factor (HIF) product candidate. Prior to these roles, Hasnain held senior positions at Relypsa, Inc. (acquired by Galapagos NV), Cubist Pharmaceuticals (acquired by Merck), and Genentech, where he contributed to the successful launches of blockbuster drugs and navigated complex regulatory landscapes. His achievements include driving multiple successful financings, strategic partnerships, and clinical milestones, such as advancing Gossamer Bio's inhaled PDGFR, CSF1R, and c-KIT inhibitor, seralutinib, into Phase 3 trials for pulmonary arterial hypertension (PAH). Under his stewardship since the company's inception in 2017, Gossamer Bio has raised over $500 million in capital and established itself as a leader in precision immunology. At Gossamer Bio, Hasnain continues to champion a patient-centric approach, leveraging cutting-edge science to address unmet needs in severe respiratory and inflammatory diseases. His strategic vision has positioned the company for potential transformative breakthroughs, earning him recognition as a key influencer in biotech innovation.